Treatment of bipolar disorders and metabolic syndrome: implications for primary care.
Recognition of the prevalence of mood disorders and increased availability of medication options have led to calls for treating bipolar disorders in the primary care setting. Second-generation antipsychotic medications (SGAs) were initially lauded for treating bipolar disorders because of their efficacy and perceived safety relative to first-generation antipsychotic medications. Metabolic syndrome is a constellation of risk factors for cardiovascular disease and type 2 diabetes mellitus, which may emerge when treating bipolar disorders with SGAs. We conducted a search of the research literature examining the association between different SGAs and metabolic syndrome. Based on our review, we offer guidelines for monitoring patient status regarding metabolic syndrome and for providing interventions to promote healthy diet and exercise.
Bell
Paul F
PF
Heritage Valley Health System, Beaver Falls, PA 15010, USA. pbell@hvhs.org
McKenna
James P
JP
Roscoe
Brandon M
BM
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000453:epidemiology*; D002908:Chronic Disease; D015897:Comorbidity; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000453:epidemiology*; D015995:Prevalence; D011320:Primary Health Care / Q000379:methods*; D012308:Risk Management
D014150:Antipsychotic Agents